Quarterly Earnings

As its stock stumbles, web-game leader CTW heads to the Roth Conference to prove its unique anime IP and HTML5 model can deliver long-term growth.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Despite a full-year GAAP loss, AFC declares a dividend and shifts its strategy post-BDC conversion. Can it resolve legacy loans and find new growth?

After a rough earnings report sent its stock tumbling, WEBTOON Entertainment heads to key investor conferences to pitch its long-term IP and creator vision.

With record 2025 revenue and a dominant hold on the gene therapy market, Cryoport's strategic investments pave a path toward profitability.

After a strong Q4, Amprius launches a strategic roadshow to pitch its high-energy silicon anode batteries to investors and key aerospace and defense players.

The neurohealth firm surpassed revenue estimates and hit positive cash flow, but a dynamic competitive landscape and CEO transition loom ahead of its earnings call.

Amid a booming gene therapy market, Oxford Biomedica Solutions launches key investor events to showcase its strategy and secure its leadership position.

LendingTree posts a record $319.7M Q4 driven by its insurance arm, yet an adjusted loss spooks investors. Can its AI-powered strategy win them back?

Riot Platforms reports a record $647M revenue for 2025, but a staggering net loss and a strategic pivot to data centers raises critical questions.

James River Group flips a $94M loss to a $30.1M profit, driven by strategic underwriting, cost cuts, and a pivotal move from Bermuda to Delaware.

Colombia's energy giant is set to reveal its 2025 performance, testing its diversification strategy against falling oil prices and high investor expectations.

After a major turnaround, Genetix Biotherapeutics announces its first profitable quarter and plans to double production of its high-stakes gene therapies.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

HVAC giant AAON reports record 2025 sales but lower earnings due to massive investments. A $1.83B backlog signals a powerful 2026 rebound.

Nike's rescheduled Q3 earnings report on March 31 amplifies anxiety as the giant battles tariffs, a China slump, and deep market skepticism.

A class action lawsuit alleges hospital operator Ardent Health misled investors by hiding financial risks, leading to a 33% stock price collapse.

National CineMedia's revenue outpaced attendance in a strong Q4, but a full-year loss and weak 2026 forecast raise questions about its future strategy.

French marketing giant DEKUPLE reports stellar 2025 growth, driven by strategic acquisitions, AI integration, and a bold international expansion strategy.